Christopher S. Klein commenced his commercial real estate career in 1982, when he began working for Robert S. Wilson Investments, a medium sized developer.

Within a year, Mr. Klein was asked to join Wilson & Wilson, a development company formed by a departing principal of Robert S. Wilson Investments. He served as Project Manager for the development of five shopping centers totaling more than 410,000 sq. ft. of space and two office buildings totaling 100,000 sq. ft.

In 1985, Mr. Klein became Vice President of Development for The HouReal Corporation where he was project manager for the development of over 240 acres of raw land. Mr. Klein’s responsibilities included the construction of streets and utilities and the formation of Municipal Utility Districts. Upon completion of all infrastructure, Mr. Klein sold 80+ acres of mixed-use commercial land to investment builders such as Trammell Crow Co., Crow-Western Co., Health Care and Retirement Corporation of America, Southland Corporation and First Texas Savings Association.

In March of 1997, Mr. Klein merged his accounts with Henry S. Miller Commercial and joined the firm as Vice President. At Henry S. Miller, Mr. Klein completed over 120 transactions, many of which were with national and regional clients such as Progressive Insurance, Premier Car Rental, Staff Force, Inc., Health Management Services, Inc., and La Petite Academy.

In March 2001, Mr. Klein joined Colliers International as a listing specialist for office and warehouse buildings. Since that time, Mr. Klein has sold more than 110 office and/or industrial buildings, as well as over 450 acres of land to user developers. This is in addition to his leasing over 650,000 square feet of industrial space on behalf of tenants and landlords.

Within a year of joining Colliers International, Mr. Klein started a Biotechnology Initiative with three associates at the firm. Since starting the initiative, Mr. Klein has listed and sold The Spectrum Commerce Center, a 150-acre business technology park, the former Guidant stint manufacturing facility, the Pace Analytical Lab, and represented PharmaFrontiers on their acquisition of Opexa Pharmaceuticals’ real estate holdings.